In brief
Daphne Koller, CEO of insitro and co-founder of Coursera, argues that AI can do for biology what calculus did for physics: make it predictable enough to manage. Drug discovery fails mostly because researchers cannot predict in advance what will work in people. Her answer is to pair machine learning with large amounts of human and lab-grown cell data, so that better targets are chosen before expensive trials begin.
The central tension is between big promise and slow, uncertain reality. Koller describes a possible ALS breakthrough, but says nothing is proven until a human trial, and some regulatory steps simply take time. Around that sit worries about funding, immigration and regulation, and a closing view that humans and machines must work as partners, with society regulating uses of AI rather than the technology itself.
Questions
What does Daphne Koller mean by 'calculus is to physics as AI is to biology'?
She means a field becomes manageable once you can predict what will happen in experiments. Calculus gave physics that power, and she thinks AI plus better measurement can start to give biology a similar predictive ability.
Why do most new drugs fail in clinical trials?
Koller says researchers cannot predict up front which ideas will help people, partly because early tests often use animals like mice. So more than 90% of drugs fail once they reach human trials.
What does insitro actually do differently from traditional drug companies?
It combines machine learning with two kinds of data: measurements from humans linking genetics to health outcomes, and large amounts of data generated in its own lab from cells. The goal is to predict which treatment ideas are more likely to work before human trials.
Is insitro competing with big pharma or working with it?
Koller says both. insitro's ALS work is a collaboration with Bristol Myers Squibb, and Lilly makes certain molecules for it, but it may compete where others target the same disease. She adds that the real enemy is the disease.
How does Koller think people should prepare for AI taking jobs?
She says technology has always removed jobs, but human creativity remains a partner to machines. She advises building skills like connecting ideas across fields and structured thinking, while governments plan for the disruption.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Daphne Koller says calculus gave Newtonian physics a formal way to predict how systems such as rolling balls and pendulums behave.
“calculus was that for Newtonian physics. Whether it's a ball rolling down a hill or a pendulum swinging, we were able to make predictions about what a system will do.”
0:06:55 · Daphne Koller · Calculus analogy
Daphne Koller says the name insitro reflects the integration of in silico (computer-based) work and in vitro (lab-based) work.
“insitro is the synthesis, the deep integration of in silico, which means in silico on the computer, and in vitro, which means in the lab.”
0:10:44 · Daphne Koller · Company name
Daphne Koller says she felt humbled and unworthy when she received her MacArthur award.
“when I did get that MacArthur Award, I actually felt very humbled and unworthy”
0:09:03 · Daphne Koller · MacArthur award
Daphne Koller describes her co-founding of Coursera as bringing the web to education in a meaningful way.
“And you can think about what we did in Coursera as the kind of bringing the web in a truly meaningful way to education.”
0:10:44 · Daphne Koller · Coursera
Daphne Koller says her parents were academics and she expected to remain an academic until retirement.
“My parents were academics. I was convinced I would retire as an academic, be a professor emeritus like my father.”
0:11:30 · Daphne Koller · Early career
Daphne Koller says she got into computers at age 12 while her father was on sabbatical in the United States.
“I got into computers actually when we were in sabbatical, when my father was here on sabbatical in the United States. And I was 12 years old.”
0:12:42 · Daphne Koller · Computing origins
Daphne Koller says the machine learning revolution began in 2012 while she was at Coursera, and that by 2016 she noticed it was not yet making a big impact in life sciences.
“because I'd actually been at Coursera when the machine learning revolution in 2012 started, in 2016, I lifted my head over the trenches.”
0:15:12 · Daphne Koller · Machine learning · 2016
Daphne Koller says she spent time at Calico after Coursera, where she first learned how drug discovery works.
“I spent some time at Calico, which is a great company and learned about drug discovery for the first time.”
0:15:48 · Daphne Koller · Calico
Daphne Koller says drug candidates fail more than 90% of the time once they enter clinical trials.
“And then you push that into the clinic and it fails over 90 % of the time.”
0:16:19 · Daphne Koller · Clinical trial failure
Co-host Kristen Stoller says bringing a drug to market takes 10 to 15 years at best.
“It takes so long to bring a drug to the market, 10 to 15 years at best.”
0:03:58 · Kristen Stoller · Drug development time
Daphne Koller says UK Biobank enrolled half a million people who agreed to have their DNA and other trait measurements recorded.
“they got half a million people to agree to have their DNA measured, as well as a whole bunch of other what we call phenotypic measurements, which are various traits.”
0:20:43 · Daphne Koller · UK Biobank
Daphne Koller says the UK Biobank dataset was very Eurocentric and that governments with more diverse populations could build similar resources.
“access to more diverse populations, because the UK Biobank was very Eurocentric”
0:22:28 · Daphne Koller · Data diversity
Daphne Koller says ALS has four approved drugs that extend life by two to three months, and patients typically live three to five years.
“There are four approved drugs. They extend lifespan by two to three months. The patients have a three to five year lifespan.”
0:24:59 · Daphne Koller · ALS treatment
Daphne Koller says Eli Lilly makes a particular type of molecule for insitro because Lilly has capacity and capabilities insitro lacks.
“We have actually an kind of inverse collaboration with Lilly where they have extra capacity and capabilities in making a particular type of molecules that isn't within our sweet spot, and they're making that for us.”
0:29:42 · Daphne Koller · Pharma partnership
Daphne Koller says regulatory toxicity requirements for a drug candidate take about a year to complete and are hard to speed up.
“there are a certain set of requirements that regulators require, for example, on toxicity that just take as long as it takes a year to do these experiments.”
0:27:36 · Daphne Koller · Drug regulation
Daphne Koller says roughly 50 to 60 percent of startups in the United States have been founded by immigrants.
“even startups as a whole, something on the order of 50 to 60% have been founded by immigrants.”
0:32:57 · Daphne Koller · Immigration
Daphne Koller says the U.S. Food and Drug Administration has embraced AI much more than in previous years.
“I mean, even the FDA has moved to embrace AI much more now than it's had in the past few years.”
0:34:34 · Daphne Koller · FDA and AI
Daphne Koller attributes the Bay Area's success partly to Stanford and Berkeley, along with a talent pipeline and available investment money.
“The Bay Area has been the success that it is because it is home to two of the greatest universities in the world, Stanford and Berkeley.”
0:36:13 · Daphne Koller · Silicon Valley
Daphne Koller says insitro's stated values include 'create together' and 'engage with respect'.
“Create together is one of our values. Engage with respect is another one.”
0:38:40 · Daphne Koller · Company culture
Daphne Koller says insitro grew to about 50 people just as the pandemic began, which distracted the company from adding decision and governance processes.
“I will use as an excuse that when we hit 50 was also when the pandemic hit.”
0:39:41 · Daphne Koller · Company growth
Daphne Koller says AI used as a therapy aid has no emotions or consciousness and works like a sophisticated mirror for the user.
“There's no emotions on the other side. There's no sentience. There's no consciousness.”
0:14:10 · Daphne Koller · AI therapy
Daphne Koller argues that AI harms should be handled by regulating specific uses rather than the technology itself.
“it's not about regulating the tool. It's about regulating the use case.”
0:49:44 · Daphne Koller · AI regulation
Daphne Koller says insitro's 'pipeline through platform' strategy aims to build a repeatable engine that produces multiple drugs, not just one.
“we are committed to something we call pipeline through platform. And that means that we don't just make a drug that makes people better.”
0:50:51 · Daphne Koller · Business strategy